Description

HUMIRA® (adalimumab) developed by AbbVie is a biologic therapy administered as a subcutaneous injection. It is approved to treat the following autoimmune diseases in the United States, Canada and Mexico (collectively, North America) and in the European Union:

Condition

• Rheumatoid arthritis (moderate to severe)
• Psoriatic arthritis
• Ankylosing spondylitis
• Crohn's disease (moderate to severe)
• Plaque psoriasis (moderate to severe chronic)
• Juvenile idiopathic arthritis (moderate to severe polyarticular)
• Ulcerative colitis (moderate to severe)
• Non-radiographic axial spondyloarthritis
• Pediatric Crohn's disease (moderate to severe)
• Hidradenitis suppurativa (moderate to severe)
• Pediatric enthesitis-related arthritis
• Non-infectious intermediate, posterior and panuveitis
• Pediatric ulcerative colitis (moderate to severe)
• Pediatric uveitis 

Humira is also approved in Japan for the treatment of intestinal Behçet's disease, generalized pustular psoriasis, and pyoderma gangrenosum. Humira is sold in numerous other markets worldwide, including Japan, China, Brazil and Australia.

Revenue (2024):

• For 20 years, AbbVie's Humira (adalimumab) has been one of the world's highest-selling pharmaceutical product in history. Since losing exclusivity in 2023, Humira has encountered direct competition from biosimilars in the U.S. AbbVie expects this to lead to a substantial drop in Humira's sales, which may negatively impact the company’s overall revenue and operating earnings.
• In 2024, Sales of Humira ($8.993 billion) represented 16% of the Company’s total sales.
• Global Humira sales decreased 37% in 2024. In the United States, Humira sales decreased 41% in 2024 primarily driven by direct biosimilar competition following loss of exclusivity on January 31, 2023. (US: $7.142 billion, 2024 vs $12.16 billion, 2023). Internationally, Humira revenues decreased 13% in 2024 primarily driven by the continued impact of direct biosimilar competition.

AbbVie forecasts 2025

AbbVie executives report that the company’s immunology drugs, Skyrizi (risankizumab) and Rinvoq (upadacitinib), are gaining traction in the inflammatory bowel disease (IBD) market as competition from Humira biosimilars intensifies. To offset declining Humira sales, AbbVie is aggressively promoting these newer therapies, now projecting they will generate over $31 billion in 2027 — a $4 billion increase from earlier estimates.

Speaking at the 2025 J.P. Morgan Healthcare Conference in San Francisco, CEO Rob Michael noted that despite Humira’s decline, only around 20% of patients have switched to biosimilars, with many physicians instead transitioning to AbbVie’s newer immunology treatments (Skyrizi & Rinvoq). Additionally, while facing biosimilar competition, AbbVie has managed to preserve Humira’s market share with pharmacy benefit managers (PBMs) over the past year by lowering its net price.

HUMIRA Cost:

The list price, also known as the Wholesale Acquisition Cost (WAC), for a 4-week supply of HUMIRA*, is $6,922.62 as of January 6, 2025. The WAC may not reflect the price paid by patients.

Description

SKYRIZI® (risankizumab) developed by AbbVie is an interleukin-23 (IL-23) inhibitor that selectively blocks IL-23 by binding to its p19 subunit. It is a biologic therapy approved to treat the following autoimmune diseases in North America, the European Union and Japan:

Condition:

• Plaque psoriasis (moderate to severe)
• Psoriatic arthritis
• Crohn's disease (moderate to severe)
• Ulcerative colitis (moderate to severe)

Skyrizi is also approved in Japan for the treatment of erythrodermic psoriasis in patients who have an inadequate response to conventional therapies, for generalized pustular psoriasis, and for palmoplantar pustulosis in patients who have an inadequate response to conventional therapies.

Revenue (2024):

• In 2024, Sales of Skyrizi ($11.718 billion) represented 20.8% of the Company’s total sales.
• Net revenues for Skyrizi increased 51% in 2024 primarily driven by continued strong market share uptake as well as market growth across all indications.
• In 2024, the change in fair value reflected higher estimated Skyrizi sales and the passage of time, partially offset by higher discount rates.

 AbbVie forecasts 2025

Skyrizi: >$17B Global Sales in 2027 ($11.5B from PsO/PsA; $5.5B from IBD)

Expiration Dates:

• Year of Expiration (U.S.): 2033

SKYRIZI Cost:

• The list price, also known as the Wholesale Acquisition Cost (WAC), for one dose of SKYRIZI is $22,383.49 as of January 6, 2025. The WAC may not reflect the price paid by patients. 

Description

RINVOQ® (upadacitinib) developed by AbbVie is an oral, once-daily selective and reversible JAK inhibitor that is approved to treat the following inflammatory diseases in North America, the European Union and Japan

Condition:

• Rheumatoid arthritis (moderate to severe)
• Psoriatic arthritis
• Ankylosing spondylitis
• Atopic dermatitis (moderate to severe)
• Non-radiographic axial spondyloarthritis
• Crohn's disease (moderate to severe)
• Ulcerative colitis (moderate to severe)
• Active polyarticular juvenile idiopathic arthritis

 RINVOQ is sold in numerous other markets worldwide, including China, Brazil, and Australia. In the United States, a liquid formulation (RINVOQ LQ) is also approved for use in pediatric patients with psoriatic arthritis and polyarticular juvenile idiopathic arthritis

Revenue (2024):

• In 2024, Sales of RINVOQ ($ 5.971billion) represented 10.5% of the Company’s total sales.
• Net revenues for Rinvoq increased 53% in 2024 primarily driven by continued strong market share uptake as well as market growth across all indications.
• In 2024, the change in fair value reflected higher estimated Skyrizi sales and the passage of time, partially offset by higher discount rates.

 AbbVie forecasts 2025

Rinvoq: >$10B Global Sales in 2027 ($4.5B from Rheum; $3.2B from IBD; $2.3B from Derm)

Expiration Dates:

• Year of Expiration (U.S.): 2033

RINVOQ® Cost:

• The list price, also known as the Wholesale Acquisition Cost (WAC), for a 30-day supply of RINVOQ, is $6,752.77 as of January 6, 2025. The WAC may not reflect the price paid by patients.

Description

STELARA® (ustekinumab) developed by Johnson & Johnson is approved to treat the following autoimmune diseases:

Condition

• Plaque psoriasis (moderate to severe)
• Psoriatic arthritis
• Crohn's disease (moderate to severe)
• Ulcerative colitis (moderate to severe)

Revenue (2024):

• Sales of the Company’s second largest product, STELARA (ustekinumab) accounted for approximately 11.7% ($10.361 billion) of the Company's total revenues for fiscal 2024.
• Sales of STELARA in the United States were approximately $6.7 billion in fiscal 2024
• About 75% of the sales are from IBD.
• STELARA decline driven by inventory dynamics and share loss primarily due to EU biosimilar entrants, partially offset by market growth and net patient mix.
• According to patent settlement and license agreements, the Company expects continued launches of biosimilar versions of STELARA in Europe and the United States in 2025 which will impact the Company’s sales of STELARA.·

STELARA® Cost:

• The list price of STELARA® is $25,497.12 every 8 weeks for the 90 mg dose as of March 2022. List price does not reflect a patient’s out-of-pocket cost and does not include samples, vouchers, the cost of administering the medication, or pharmacy fees. 

Description

Cosentyx (secukinumab) developed by Novartis is an injectable, fully human monoclonal antibody that selectively inhibits interleu-kin-17A (IL-17A), a cytokine involved in several immune-logical diseases. It is approved in the US, the EU and other countries to treat:

Condition

• Plaque psoriasis (moderate to severe)
• Psoriatic arthritis
• Non-radiographic axial spondyloarthritis
• Ankylosing spondylitis
• Enthesitis-re-lated arthritis (ERA)
• Hidradenitis Suppu-rativa (HS) (moderate to severe)

An intravenous formulation of Cosentyx is approved in the US for the treatment of adults with active PsA, AS and nr-axSpA.

Revenue (2024):

• Cosentyx (USD 6.1 billion, +23%, +25% cc) sales grew mainly in the US, emerging growth markets and Europe, driven by strong demand from launches (including the HS indication and the IV formulation in the US) and volume growth in core indications (PsO, PsA, AS and nr-axSpA)
• #1 IL-17 in US dynamic market
• ~60% leader in hidradenitis suppurativa - US (NBRx shares)
• Leading originator biologic in EU and China
• Since initial approval in 2015, Cosentyx has shown sustained efficacy and a robust safety profile, treating more than 1.7 million patients across eight indications

Expiration Dates:

• Year of Expiration (U.S): 2029
• Year of Expiration (EU): 2030

COSENTYX® Cost:

• The list (or wholesale) price for COSENTYX, as of July 2025 is $7,936.48 a month for either a 150-mg or a 300-mg dose strength self-injection package and $4,401.32 per intravenous infusion. The list price may not reflect the price paid by patients; most patients with prescription coverage will pay less.

Description

DUPIXENT® (dupilumab) jointly developed by Sanofi and Regeneron under a global collaboration agreement is a fully human monoclonal antibody that inhibits the signaling of the interleukin-4 (IL-4) and interleukin-13 (IL-13) pathways and is not an immunosuppressant. Dupixent is available in all major markets including the US (since April 2017), most European Union countries (the first launch was in Germany in December 2017), Japan (since April 2018), and China (since June 2020) to treat: 

Condition

• Atopic dermatitis (AD) – LARGEST REVENUE SHARE
• Asthma
• Chronic rhinosinusitis with nasal polyposis (CRSwNP)
• Eosinophilic esophagitis (EoE)
• Prurigo nodularis (PN)
• Chronic spontaneous urticaria (CSU)
• Chronic obstructive pulmonary disease (COPD) 

Revenue (2024): (Sanofi records global net product sales of Dupixent; Regeneron records their share of profits in connection with global sales. Regeneron co-commercializes Dupixent in the United States and in certain countries outside the United States. Regeneron and Sanofi equally share profits from sales within the United States, and share profits outside the United States on a sliding scale based on sales starting at 65% (Sanofi)/35% (Regeneron) and ending at 55% (Sanofi)/45% (Regeneron))

• Dupixent generated net sales of €13,072 million in 2024 representing 31.8% of Sanofi’s net sales for the year and is Sanofi’s biggest product in terms of sales
• In the United States, sales of Dupixent reached €9,544 million (+17.2% CER), driven by continuing strong demand in the product’s approved indications: atopic dermatitis (AD), asthma, chronic rhinosinusitis with nasal polyposis (CRSwNP), eosinophilic esophagitis, and prurigo nodularis
• In Europe, the product’s net sales for 2024 totaled €1,618 million, up 31.9% CER, reflecting continued growth in all approved indications and emerging sales in chronic obstructive pulmonary disease (COPD)
• In the Rest of the World region, Dupixent posted net sales of €1,910 million 

Forecast: 

Dupixent is currently expected to reach sales of around €22 billion in 2030, in line with the current Sanofi’s ambition and expected future launches from pipeline.

Expiration Dates:

• Year of Expiration (U.S): Composition of Matter - March 28, 2031
• Year of Expiration (EU): Composition of Matter : October 27, 2029
• Year of Expiration (Japan): Composition of Matter : October 27, 2029 – October 27, 2034

DUPIXENT ® Cost:

• The list (or wholesale) price for DUPIXENT, as of 1/3/2025 is $3,993.36 USD per carton. . A monthly supply of DUPIXENT (300 mg or 200 mg) is defined as 2 injections per month. The list price may not reflect the price paid by patients; most patients with prescription coverage will pay less.